Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Urinary Tract Infection

Free Subscription Articles published in Int J Antimicrob Agents Retrieve available abstracts of 37 articles: HTML format

Single Articles

August 2026
1. YUAN J, Fan D, Wu H, Jia B, et al
   In reply to Letter to Editor regarding "A multicenter, randomized, double-blind, imipenem/cilastatin-controlled clinical study of cefiderocol for the treatment of complicated urinary tract infections caused by Gram-negative pathogens in Chinese adults
   Int J Antimicrob Agents. 2026 Aug 28:107983.
   PubMed    
   
   
   
2. GOMEZ-ZORRILLA S, Sabate RA, Montesinos IL, Brase A, et al
   Impact of an Antimicrobial Stewardship intervention on clinical and economic outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) for urinary tract infections: a quasi-experimental study.
   Int J Antimicrob Agents. 2026 Aug 10:107955.
   PubMed     Abstract available
   
   
   
3. SETIAWAN E, Gonzalez A, Wolky SA, Cotta MO, et al
   Population pharmacokinetics of total and free ceftriaxone in critically ill and non-critically ill hospitalised adult patients.
   Int J Antimicrob Agents. 2026;67:107817.
   PubMed     Abstract available
   
   
   June 2026
4. CHAI L, Luo H, Li Q
   Comment on "A Multicenter, Randomized, Double-Blind, Imipenem/Cilastatin-Controlled Clinical Study of Cefiderocol for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Pathogens in Chinese Adults".
   Int J Antimicrob Agents. 2026 Jun 18:107887.
   PubMed    
   
   
   May 2026
5. OZDEMIR C, Paul T, Egoh K, Wanford JJ, et al
   Burden and Global Distribution of Antimicrobial Resistance in Non-Bloodstream Infections Among Adults with Cirrhosis: A Systematic Review and Proportional Meta-Analysis.
   Int J Antimicrob Agents. 2026 May 27:107849.
   PubMed     Abstract available
   
   
   April 2026
6. RIAZ A, Riaz R
   Targeted Use of Sulopenem in Multidrug-Resistant Uncomplicated Urinary Tract Infections.
   Int J Antimicrob Agents. 2026 Apr 30:107828.
   PubMed    
   
   
   
7. SINGH N, Srivastav M
   Comment on "ESBL-producing Escherichia coli bacteremic urinary tract infections: clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study".
   Int J Antimicrob Agents. 2026 Apr 20:107820.
   PubMed    
   
   
   
8. YUAN J, Fan D, Wu H, Jia B, et al
   A Multicenter, Randomized, Double-Blind, Imipenem/Cilastatin-Controlled Clinical Study of Cefiderocol for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Pathogens in Chinese Adults.
   Int J Antimicrob Agents. 2026 Apr 15:107812.
   PubMed     Abstract available
   
   
   
9. ZAHAVI I, Kunwar D, Olchowski J, Dallasheh H, et al
   In reply to the Letter to the Editor regarding "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis".
   Int J Antimicrob Agents. 2026 Apr 6:107800.
   PubMed    
   
   
   
10. FALAGAS ME, Romanos LT, Katritsi ED, Tzvetanova ID, et al
    Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies.
    Int J Antimicrob Agents. 2026;67:107723.
    PubMed     Abstract available
    
    
    March 2026
11. KUNWAR D, Zahavi I, Olchowski J, Dallasheh H, et al
    In reply to the Letter to Editor regarding "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis".
    Int J Antimicrob Agents. 2026 Mar 28:107791.
    PubMed    
    
    
    
12. GOMEZ-ZORRILLA S, Rodriguez-Cabale G, Montesinos IL, Alanti SS, et al
    "ESBL-producing Escherichia coli bacteremic urinary tract infections: clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study".
    Int J Antimicrob Agents. 2026 Mar 20:107787.
    PubMed     Abstract available
    
    
    
13. WANG C, Chen J, Yang H, Jiang M, et al
    Comment on'Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis'.
    Int J Antimicrob Agents. 2026 Mar 8:107777.
    PubMed    
    
    
    
14. MAJI C, Srinivasan H, Biradar A, Jauhari R, et al
    Comment on "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis".
    Int J Antimicrob Agents. 2026 Mar 5:107771.
    PubMed    
    
    
    
15. CHEN Q
    Comment on "Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis".
    Int J Antimicrob Agents. 2026 Mar 3:107770.
    PubMed    
    
    
    February 2026
16. PIMENTA-DE-SOUZA P, Ramos-Silva A, Sandes V, Portella P, et al
    Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map.
    Int J Antimicrob Agents. 2026;67:107710.
    PubMed     Abstract available
    
    
    
17. LIAO J, Li C, Liu J, Wu W, et al
    Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring.
    Int J Antimicrob Agents. 2026;67:107697.
    PubMed     Abstract available
    
    
    December 2025
18. KUNWAR D, Zahavi I, Olchowski J, Dallasheh H, et al
    Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2025 Dec 22:107696.
    PubMed     Abstract available
    
    
    September 2025
19. COOK JD, Hooey PB, Salazar KC, Clark JR, et al
    Results of TOR001: an open-label single patient study using targeted bacteriophage therapy for the treatment of a chronic urinary tract infection.
    Int J Antimicrob Agents. 2025 Sep 8:107613.
    PubMed     Abstract available
    
    
    
20. BENITEZ-CANO A, Liu X, Xu H, Tang X, et al
    Optimizing Linezolid Dosing for Nosocomial Urinary Tract Infections in Critically Ill Patients with Renal Impairment.
    Int J Antimicrob Agents. 2025 Sep 5:107610.
    PubMed     Abstract available
    
    
    
21. ABRIL D, Solorzano P, Leal AL, Forero-Hurtado D, et al
    Ceftazidime/avibactam resistance in Enterobacter cloacae due to the acquisition of a small pHAD28-like plasmid harbouring bla(KPC-33).
    Int J Antimicrob Agents. 2025;66:107540.
    PubMed     Abstract available
    
    
    September 2024
22. LI P, Xu Q, Ding L, Zhang X, et al
    Q48K mutation in the type IB nitroreductase NrmA is responsible for nitrofurantoin resistance in Enterococcus faecium.
    Int J Antimicrob Agents. 2024;64:107277.
    PubMed     Abstract available
    
    
    
23. RODRIGUEZ-RUIZ JP, Lin Q, Van Heirstraeten L, Lammens C, et al
    Long-term effects of ciprofloxacin treatment on the gastrointestinal and oropharyngeal microbiome are more pronounced after longer antibiotic courses.
    Int J Antimicrob Agents. 2024;64:107259.
    PubMed     Abstract available
    
    
    August 2024
24. YANG W, Chen J, Yang F, Ji P, et al
    Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection.
    Int J Antimicrob Agents. 2024;64:107211.
    PubMed     Abstract available
    
    
    
25. GIMENEZ-PEREZ M, Hernandez S, Padulles A, Boix-Palop L, et al
    Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia.
    Int J Antimicrob Agents. 2024;64:107202.
    PubMed     Abstract available
    
    
    July 2024
26. MESCHIARI M, Asquier-Khati A, Tiseo G, Luque-Paz D, et al
    Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Int J Antimicrob Agents. 2024;64:107186.
    PubMed     Abstract available
    
    
    December 2023
27. SHI H, Zeng L
    Comment on: Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Dec 9:107059.
    PubMed    
    
    
    November 2023
28. KIM C, Choi YH, Choi JY, Choi HJ, et al
    Translation of Machine Learning-Based Prediction Algorithms to Personalised Empiric Antibiotic Selection: A Population-Based Cohort Study.
    Int J Antimicrob Agents. 2023;62:106966.
    PubMed     Abstract available
    
    
    September 2023
29. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    PubMed     Abstract available
    
    
    
30. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    PubMed     Abstract available
    
    
    April 2023
31. HUNG KC, Tsai WW, Hsu CW, Lai CC, et al
    Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Apr 24:106830.
    PubMed     Abstract available
    
    
    
32. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    PubMed     Abstract available
    
    
    March 2023
33. DE OCA JEM, Veve MP, Zervos MJ, Kenney RM, et al
    Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections.
    Int J Antimicrob Agents. 2023 Mar 31:106800.
    PubMed     Abstract available
    
    
    August 2022
34. BELMONT-MONROY L, Ribas-Aparicio RM, Gonzalez-Villalobos E, Perez-Ramos JA, et al
    Molecular typification of Escherichia coli from community-acquired urinary tract infections in Mexico.
    Int J Antimicrob Agents. 2022 Aug 26:106667.
    PubMed     Abstract available
    
    
    April 2022
35. FOSSE PE, Brinkman KM, Brink HM, Conner CE, et al
    Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents.
    Int J Antimicrob Agents. 2022;59:106560.
    PubMed     Abstract available
    
    
    March 2022
36. TUTONE M, Johansen TEB, Cai T, Mushtaq S, et al
    SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Int J Antimicrob Agents. 2022 Mar 17:106574.
    PubMed     Abstract available
    
    
    January 2022
37. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Urinary Tract Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum